Moreover, PRMT1 inhibition by DCPT1061 not only inhibited tumor growth but also sensitized ccRCC to sunitinib treatment <i>in vivo</i> by attenuating sunitinib-induced upregulation of LCN2-AKT-RB signaling. Here, RB1 is linked to nonpapillary renal cell carcinoma.